Alembic Pharmaceuticals
add_icon

Alembic Pharmaceuticals

656.20
-20.85
(-3.08%)
Market Cap
12,898.47 Cr
PE Ratio
21.24
Volume
60,922.00
Day High - Low
673.55 - 650.00
52W High-Low
1,107.90 - 635.80
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
12,898.47 Cr
EPS
29.68
PE Ratio
21.24
PB Ratio
2.50
Book Value
270.62
EBITDA
1,050.80
Dividend Yield
1.63 %
Industry
Healthcare
Return on Equity
11.22
Debt to Equity
0.18
Analyst Rating and Forecast
- By Refinitiv from12 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+50.00 %
+50.00 %
Hold
Hold+41.67 %
+41.67 %
Sell
Sell+8.33 %
+8.33 %
Forecast For
Actual

Company News

View All News
Caret
positive
Alembic Pharmaceuticals announces Chirayu Amin's appointment as Executive Chairman effective April 1, 2026, for a five-year term, following shareholder approval at the 15th AGM.
positive
Alembic Pharmaceuticals announces re-appointment of Pranav Amin as Managing Director for 5 years effective April 1, 2026, following shareholder approval at 15th AGM held on August 5, 2025.
positive
Alembic Pharmaceuticals officially appoints Mr. Rajkumar Baheti as Non-Executive Non-Independent Director effective April 1, 2026, following successful postal ballot approval with 99.74% shareholder support.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,693.60
#1 4,06,351.37
37.86
#1 54,729.00
9.71
#1 10,980
16.07
37.98
5,856.50
1,55,471.67
63.26
9,712.00
18.67
2,191
-1.02
33.24
3,987.20
1,34,944.97
61.20
11,539.40
6.99
1,911
26.24
32.75
2,274.50
1,03,954.48
22.26
22,909.50
13.74
3,306
#1 37.44
47.35
1,217.30
1,01,601.09
18.27
33,741.20
16.73
5,725
-15.28
39.36
1,192.40
96,319.77
21.31
28,409.50
7.12
5,291
-57.18
26.86
864.25
86,963.77
#1 17.29
23,511.00
18.55
4,615
-0.32
41.42
1,998.50
82,499.09
45.81
12,744.20
#1 20.90
2,007
7.65
41.40
1,333.70
77,461.51
22.37
32,345.60
9.43
3,484
7.59
64.38
5,258.00
62,867.28
25.87
13,458.30
3.70
2,216
1.90
42.54
Growth Rate
Revenue Growth
7.32 %
Net Income Growth
-5.49 %
Cash Flow Change
-89.05 %
ROE
-12.21 %
ROCE
6.31 %
EBITDA Margin (Avg.)
1.82 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
504
582
1,003
918
630
737
880
777
742
648
797
840
854
863
1,129
1,022
930
952
1,241
1,210
1,243
1,342
1,460
1,317
1,306
1,328
1,313
1,291
1,426
1,263
1,475
1,510
1,407
1,498
1,605
1,634
1,521
1,564
1,678
1,703
1,784
1,717
1,919
1,892
Expenses
405
478
629
532
484
580
702
632
606
547
610
653
680
712
825
776
749
757
895
884
926
934
1,014
949
960
1,090
1,054
1,030
1,268
1,255
1,244
1,274
1,203
1,288
1,387
1,364
1,257
1,325
1,409
1,433
1,498
1,430
1,595
1,627
EBITDA
99
103
375
386
146
158
178
146
136
102
187
188
174
151
305
246
181
195
346
326
318
408
447
368
346
238
259
261
158
9
231
236
205
210
218
269
263
239
270
270
286
287
324
265
Operating Profit %
19 %
18 %
37 %
42 %
23 %
21 %
20 %
19 %
18 %
16 %
23 %
22 %
20 %
18 %
27 %
24 %
19 %
20 %
28 %
27 %
23 %
30 %
30 %
28 %
25 %
18 %
18 %
19 %
10 %
1 %
16 %
16 %
14 %
13 %
13 %
16 %
17 %
15 %
15 %
15 %
15 %
16 %
17 %
13 %
Depreciation
11
13
13
22
24
19
21
21
22
22
26
26
32
28
29
29
30
35
36
42
44
42
44
47
51
53
55
56
123
67
68
67
74
66
68
69
70
69
71
70
69
74
76
80
Interest
0
1
1
1
2
1
1
1
2
1
0
1
1
2
6
6
5
5
7
7
8
7
5
2
3
2
5
4
7
9
12
15
14
14
16
15
11
13
19
22
25
24
24
23
Profit Before Tax
89
91
362
364
120
137
157
124
112
79
161
161
141
122
270
211
146
155
303
276
266
360
398
318
292
183
200
201
29
-67
151
155
116
130
135
185
183
157
180
178
192
190
224
162
Tax
18
19
73
95
29
33
37
37
19
12
39
30
47
32
70
42
23
36
52
49
62
66
73
33
49
24
36
29
7
-2
18
33
-36
9
-2
4
5
23
27
40
35
37
40
30
Net Profit
70
72
289
269
91
104
120
87
93
67
122
131
94
90
200
169
124
120
250
227
204
293
325
286
243
158
164
172
22
-66
133
122
153
121
137
180
178
135
153
138
157
154
184
132
EPS in ₹
3.73
3.72
15.30
14.26
4.82
5.50
6.36
4.59
4.94
3.54
6.45
6.93
4.98
4.80
10.61
9.01
6.58
6.56
13.06
12.42
11.93
15.99
17.24
14.88
12.75
8.37
8.34
8.74
1.11
-3.35
6.78
6.20
7.76
6.14
6.95
9.23
9.07
6.84
7.79
7.01
7.98
7.85
9.40
6.76

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
Fixed Assets
547
708
799
993
1,159
1,552
1,788
1,798
2,398
2,547
2,524
Current Assets
891
1,511
1,373
1,825
1,958
2,463
2,652
2,861
2,910
3,079
4,088
Capital Work in Progress
83
93
396
1,010
1,551
1,846
2,183
2,304
601
524
837
Investments
0
53
50
42
49
18
236
118
96
93
127
Other Assets
1,011
1,575
1,444
1,896
2,019
2,573
2,502
2,902
3,087
3,282
4,285
Total Equity & Liabilities
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
Current Liabilities
684
747
693
1,144
1,490
1,752
1,281
1,717
1,637
1,455
2,412
Non Current Liabilities
72
84
94
576
570
1,047
361
168
175
172
171
Total Equity
885
1,597
1,902
2,220
2,718
3,190
5,067
5,238
4,371
4,818
5,190
Reserve & Surplus
847
1,560
1,865
2,182
2,681
3,182
5,028
5,198
4,331
4,779
5,152
Share Capital
38
38
38
38
38
38
39
39
39
39
39

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
3
417
-286
-69
115
-127
26
-37
14
45
-37
Investing Activities
-256
-307
-486
-884
-756
-731
-840
-372
-448
-321
-568
Operating Activities
172
948
329
312
812
449
1,463
552
724
803
88
Financing Activities
87
-224
-129
503
59
155
-597
-217
-262
-438
444

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
69.48 %
69.48 %
69.48 %
69.48 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.67 %
69.67 %
69.74 %
69.74 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
4.52 %
4.46 %
4.32 %
3.94 %
4.17 %
3.94 %
3.96 %
4.05 %
4.24 %
DIIs
10.92 %
11.17 %
11.36 %
11.56 %
11.69 %
12.06 %
12.43 %
12.76 %
13.31 %
13.40 %
13.93 %
14.50 %
15.38 %
15.47 %
16.05 %
16.06 %
16.43 %
16.46 %
16.30 %
16.17 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
10.99 %
10.78 %
11.43 %
9.57 %
9.22 %
8.91 %
9.12 %
9.21 %
9.08 %
8.98 %
8.24 %
8.00 %
7.41 %
7.48 %
7.36 %
7.26 %
7.07 %
7.01 %
6.93 %
6.87 %
Others
8.61 %
8.57 %
7.73 %
9.39 %
9.47 %
9.41 %
8.84 %
8.42 %
8.00 %
8.01 %
8.22 %
3.37 %
3.14 %
3.13 %
3.04 %
2.90 %
2.88 %
2.89 %
2.99 %
2.98 %
No of Share Holders
0
0
99,809
1,01,686
1,23,059
1,10,038
1,06,437
1,01,457
1,03,811
97,607
89,552
85,212
76,567
74,829
91,429
93,944
91,336
89,013
89,969
87,000

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 4 4 5.5 10 14 10 8 11 11 0.00
Dividend Yield (%) 0.73 0.74 1.03 1.04 1.89 2.13 0.81 1.18 1.66 0.00

Announcements

Announcement under Regulation 30 (LODR)-Change in Directorate2 days ago
Announcement under Regulation 30 (LODR)-Cessation2 days ago
Announcement under Regulation 30 (LODR)-Change in Directorate2 days ago
Announcement under Regulation 30 (LODR)-Change in Directorate2 days ago
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report3 days ago
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot3 days ago
Announcement under Regulation 30 (LODR)-Change in Management3 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release7 days ago
Closure of Trading Window7 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 20, 2026
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Incorporation Of SubsidiaryMar 09, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 06, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 06, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 04, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 02, 2026
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 27, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 24, 2026
Completion Of United States Food And Drug Administration Inspection At Alembic Pharmaceuticals LimitedS Injectable Facility (F-3) At KarakhadiFeb 18, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 11, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 11, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 06, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 05, 2026
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 05, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 05, 2026
Unaudited Financial Results For Quarter And Nine Months Ended 31St December 2025Feb 05, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 05, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 05, 2026
Board Meeting Outcome for Outcome Of Board MeetingFeb 05, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 03, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementJan 31, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 27, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 21, 2026
Board Meeting Intimation for Unaudited Financial Results For The Quarter And Nine Months Ended 31St December 2025Jan 20, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 12, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 05, 2026
Closure of Trading WindowDec 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 18, 2025
Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Dec 16, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 15, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 11, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 04, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementDec 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 11, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
UTI Nifty500 Shariah Index Fund Direct-Growth
0.07%
670
0.07%
0.07%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.21%
653
-0.02%
-0.03%
DSP Nifty Smallcap 250 Index Fund Direct - Growth
0.21%
27
-0.02%
-0.02%
Navi Nifty MidSmallcap 400 Index Fund Direct - Growth
0.07%
-14
-0.01%
-0.01%
DSP Nifty 500 Index Fund Direct-Growth
0.02%
-2
0.00%
0.02%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.02%
2
0.00%
0.00%
HDFC BSE 500 Index Fund Direct - Growth
0.02%
0
0.00%
0.00%
Kotak Nifty Smallcap 250 Index Fund Direct-Growth
0.20%
0
0.00%
-0.03%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.29%
0
0.00%
-0.05%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.21%
0
0.00%
-0.02%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.02%
0
0.00%
0.00%
Baroda BNP Paribas Small Cap Fund Direct - Growth
0.00%
0
0.00%
0.00%
DSP Aggressive Hybrid Fund Direct-Growth
0.48%
0
0.00%
-0.06%
DSP ELSS Tax Saver Fund Direct Plan-Growth
0.59%
0
0.00%
-0.06%
DSP Equity Savings Fund Direct-Growth
0.19%
0
0.00%
-0.02%
DSP Healthcare Fund Direct - Growth
3.35%
0
0.00%
-0.41%
DSP Midcap Direct Plan-Growth
0.77%
0
0.00%
-0.10%
DSP Multi Asset Allocation Fund Direct - Growth
0.09%
0
0.00%
-0.02%
DSP Multicap Fund Direct - Growth
0.34%
0
0.00%
-0.05%
Bajaj Finserv Multi Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bajaj Finserv Healthcare Fund Direct-Growth
0.90%
0
0.00%
-0.12%
DSP Regular Savings Fund Direct-Growth
0.19%
0
0.00%
-0.02%
DSP Small Cap Direct Plan-Growth
0.63%
0
0.00%
-0.10%
DSP Top 100 Equity Direct Plan-Growth
0.60%
0
0.00%
-0.07%
HDFC Retirement Savings Fund - Hybrid Debt Plan Direct-Growth
0.22%
0
0.00%
-0.02%

Technical Indicators

RSI(14)
Neutral
38.38
ATR(14)
Less Volatile
24.63
STOCH(9,6)
Neutral
55.96
STOCH RSI(14)
Neutral
76.56
MACD(12,26)
Bullish
2.10
ADX(14)
Strong Trend
31.77
UO(9)
Bearish
49.27
ROC(12)
Downtrend And Accelerating
-3.21
WillR(14)
Neutral
-72.38

About Alembic Pharmaceuticals

Alembic Pharmaceuticals is an India-based company that manufactures and markets generic pharmaceutical products globally. It operates in India Formulations, International Generics, and Active Pharmaceutical Ingredients (API) segments. The company has state-of-the-art research and manufacturing facilities approved by regulatory authorities, including the US FDA. Alembic produces a range of generics across...more
Chairperson NameChirayu R Amin